Verastem highlighted a publication with two-year follow-up from its Phase 2 RAMP 201 study, reporting durable responses and disease control across KRAS-mutated and KRAS wild-type patients. Safety and tolerability remained consistent with earlier findings, and the data supported FDA accelerated approval for KRAS-mutated recurrent disease after prior systemic therapy.
Verastem highlighted a publication reporting two-year follow-up from its Phase 2 RAMP 201 study of the avutometinib-defactinib co-pack in recurrent low-grade serous ovarian cancer. The results, previously presented at the Society of Gynecologic Oncology 2026 annual meeting, showed durable responses and disease control across KRAS-mutated and KRAS wild-type patients.
Safety and tolerability remained consistent with earlier findings, with no new safety signals reported. The study data supported FDA accelerated approval for treating KRAS-mutated recurrent disease following prior systemic therapy.
